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Background. Malignant hyperthermia (MH) is a potentially lethal disease triggered by volatile
anaesthetics and succinylcholine in genetically predisposed individuals. Because of the heteroge-
netic nature of MH, a simple genetic-based diagnostic test is not feasible and diagnosis requires
an invasive open muscle biopsy followed by the in vitro contracture test (IVCT). Our aim was
to establish if measurements of halothane-induced increases in intracellular calcium ion concen-
tration [Ca2+]i in cultured human skeletal muscle cells can be used to phenotype MH suscepti-
bility and if different mutations in the ryanodine receptor (RYR1) gene affect halothane-induced
increases in [Ca2+]i.
Methods. Primary cultures of human skeletal muscle cells were established from 54 individuals
diagnosed by the IVCT according to the protocol of the European MH Group as: MH suscep-
tible (n=22), MH negative (n=18) or MH equivocal (n=14). All individuals were screened for the
presence of the most common mutations in the RYR1 gene. [Ca2+]i was measured by ¯uores-
cent digital microscopy using fura-2/AM in 10 cells from each patient at ®ve different halothane
concentrations.
Results. The halothane-induced increase in [Ca2+]i differed signi®cantly between the three
diagnostic groups. Different mutations of the RYR1 gene did not have a speci®c impact on
halothane-induced increases in [Ca2+]i.
Conclusions. Measurements of [Ca2+]i in human skeletal muscle cells can be used to pheno-
type MH susceptibility; however, we did not observe a speci®c effect of any mutation in the
RYR1 gene on the halothane-induced increase in [Ca2+]i.
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Malignant hyperthermia (MH) is a pharmacogenetic disease
triggered by halogenated anaesthetics and succinylcholine
in predisposed individuals.1±3 The incidence of MH epi-
sodes is about 1 in 15 000 anaesthetics in children and 1 in
50 000 in adults, although these ®gures may underestimate
the true prevalence, since many reactions occur in patients
who have previously come into contact with trigger agents
and had uneventful anaesthesia.4 5 Symptoms characterizing
an impending MH crisis include a rapid and sustained
increase in body temperature, skeletal muscle rigidity,
acidosis, rhabdomyolysis and tachycardia6 or any combin-
ation of the above (see review by Gronert and colleagues3).
If such a reaction is not recognized in its early phases and
treatment quickly initiated, the patient is likely to die.
In their daily lives MH-predisposition does not pose a
threat to MH-susceptible (MHS) individuals, so the major
goal of MH diagnostics is to identify susceptible individuals
before the administration of trigger agents.7 8 To date the
gold standard of MH diagnosis is the in vitro contracture test
(IVCT). This invasive procedure involves an open muscle
biopsy and in vitro challenge of muscle strips with
halothane or caffeine. According to the guidelines of the
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European MH Group, patients are then diagnosed as MHS
or MH negative (MHN) on the basis of contractile threshold
and sensitivity of the muscle bundles to halothane and
caffeine. If contracture is achieved only with either caffeine
or halothane, the patient is diagnosed as MH equivocal
(MHE).6 9
The underlying cause of MH is an abnormality in skeletal
muscle calcium metabolism.10 11 Therefore, alterations in
proteins involved in the regulation of the intracellular
calcium concentration ([Ca2+]i), such as the calcium pump,
the calcium release channel or other proteins implicated in
excitation±contraction coupling, could potentially cause
Table 1 Family of origin (a capital letter indicates members belonging to the same family, the absence of a letter indicates single members of a family),
identi®cation of malignant hyperthermia (MH)-linked ryanodine receptor (RYR1) mutation and in vitro contracture test (IVCT) of muscle biopsies. MHN=MH
negative; MHS=MH susceptible; MHE=MH equivocal
IVCT ± halothane IVCT ± caffeine
Number Status Family RYR1 mutation
Threshold (%) Contracture (g)
at 2%
Threshold (mM) Contracture (g)
at 2 mM
1 MHN A >3 0.05 >4 0
2 MHN A >3 0.15 4 0
3 MHN A >3 0.05 >4 0
4 MHN B 3 0.15 >4 0.1
5 MHN C >3 0.1 >4 0.1
6 MHN C 3 0.15 4 0
7 MHN D >3 0.15 >4 0
8 MHN D 3 0.1 4 0
9 MHN D >3 0.05 >4 0
10 MHN D >3 0.05 >4 0.05
11 MHN D >3 0.05 >4 0.05
12 MHN D >3 0.05 >4 0.05
13 MHN >3 0.1 4 0
14 MHN >3 0.05 >4 0
15 MHN >3 0.1 >4 0.1
16 MHN >3 0.1 >4 0
17 MHN >3 0 4 0.1
18 MHN >3 0.05 4 0.05
1 MHE A Arg614Cys 1 0.85 3 0
2 MHE A 1 1.15 4 0.05
3 MHE B 2 0.35 4 0.05
4 MHE B 1 0.4 4 0.1
5 MHE C 1 1.7 3 0
6 MHE D 2 0.3 4 0
7 MHE E 1 0.7 4 0
8 MHE E 1 1 3 0.05
9 MHE 2 0.3 >4 0.1
10 MHE 0.5 1.3 3 0.1
11 MHE 2 0.3 >4 0.05
12 MHE 1 1.35 3 0.05
13 MHE 2 0.4 4 0.05
14 MHE 1 0.85 3 0.05
1 MHS A Arg614Cys 0.5 5.1 0.5 2.7
2 MHS B Gly2434Arg 0.5 1.3 2 0.25
3 MHS C Val2168Met 0.5 5.1 1.5 1.2
4 MHS C Val2168Met 0.5 4.6 1.5 2.7
5 MHS C Val2168Met 0.5 4.5 1 2.35
6 MHS C Val2168Met 0.5 2.1 1.5 1.35
7 MHS D Val2168Met 0.5 3.75 1 1.45
8 MHS D Val2168Met 0.5 2.65 1 1.65
9 MHS E 0.5 3.9 1 1.9
10 MHS F Val2168Met 1 1.45 2 0.2
11 MHS F Val2168Met 0.5 3.55 1 2.25
12 MHS G 0.5 3.5 1.5 0.4
13 MHS G 0.5 3.05 1.5 0.65
14 MHS G 1 1.6 0.5 1.6
15 MHS G 0.5 2.6 1 1.3
16 MHS Val2168Met 0.5 1.8 2 0.8
17 MHS Arg2458Cys 0.5 1 1.5 0.7
18 MHS 1 2 1.5 0.4
19 MHS 0.5 1.95 1 1.3
20 MHS Val2168Met 0.5 1.7 1.5 0.7
21 MHS Val2168Met 1 1.05 1 1.3
22 MHS 1 0.9 2 0.25
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MH. Studies into the molecular mechanisms underlying this
disease have demonstrated that the ryanodine receptor
(RYR1) gene on human chromosome 19q is the primary
locus of MH.2 7 12Mutation screening has identi®ed more
than 30 mutations in the RYR1 gene so far. Although
approximately 50% of MH families have mutations in the
RYR1 gene, linkage studies have revealed that this is a
heterogenetic disease.7 12±16
The aim of the present study was to determine if
halothane-induced increases in [Ca2+]i in human skeletal
muscle cells can be used to phenotype MH susceptibility
and if different mutations in the RYR1 gene have a distinct
effect on the halothane-induced increases in [Ca2+]i.
Methods
Study protocol
In order to determine if halothane-induced increases in
[Ca2+]i in human skeletal muscle cells can be used to
phenotype MH susceptibility, we compared the results
obtained by the IVCT with results obtained by measuring
the halothane-induced increase in [Ca2+]i in cultured
skeletal muscle cells. Patients included in the study were
tested by the IVCT according to the protocol of the
European MH Group.9 On the same day, primary skeletal
muscle cell cultures were established from surplus frag-
ments of the muscle biopsies. For each patient, increases in
[Ca2+]i were measured in 10 muscle cells after exposure to
3.9, 4.6, 5.7, 7.2 or 8.6 mM halothane. These concentrations
were chosen because in a previous study17 we found that the
biggest differences in [Ca2+]i between cells from MHS and
MHN individuals were obtained in this range of halothane
concentrations.
In order to determine if different mutations have a
different effect on halothane-induced increases in [Ca2+]i,
all patients were screened for nine of the most common
mutations in the RYR1 gene (described below) and the
increases in [Ca2+]i in subjects carrying different mutations,
as well as in subjects carrying the same mutation in the
RYR1 gene, were analysed and compared.
Patient selection
We selected 54 patients from 26 families with a positive
history of MH without clinical signs of neuromuscular
disease. The age range of the patients was 8±59 yr. Twenty-
two patients were diagnosed as MHS, 18 as MHN and 14 as
MHE by IVCT. Patients were classi®ed as MHS if a
contracture force >0.2 g was elicited by at least 2%
halothane and 2 mM caffeine, as MHE if a contracture force
>0.2 g was elicited only by either caffeine or halothane, and
MHN if contractures >0.2 g were not reached with either
trigger agent. The characteristics of the individuals involved
in this study, including contractures obtained from the
muscle strips during the IVCT, family of origin and
mutation found are given in Table 1.
The protocol for the study was approved by the
University of Basel Hospital Ethics Committee and written
informed consent was obtained from patients.
Materials
Dulbecco modi®ed Eagle (DME) medium containing 4.5
mg ml±1 glucose, fetal calf serum (FCS), horse serum,
penicillin G and streptomycin was purchased from Life
Technologies Ltd, Paisley, UK. Insulin was purchased from
Eli Lilly and Co., Indianapolis, IN, USA. Cell culture
material was from Becton Dickinson GmbH, Heidelberg,
Germany. Halothane was from Halocarbon Labs, Inc.,
Hackensack, NJ, USA. The mammalian blood DNA isol-
ation kit and Taq polymerase and DNA restriction enzymes
were from Roche Molecular Biochemicals (Basel,
Switzerland). The kit for DNA isolation from tissue was
from Machery-Nagel GmbH, DuÈren, Germany. The poly-
merase chain reaction (PCR) puri®cation kit was from
Qiagen GmbH, Hilden, Germany. Fura-2/AM and ionomy-
cin were from Sigma Chemical Co., St Louis, MO, USA.
Primers were from Microsynth GmbH, Balgach,
Fig 1 Average peak change (D) in [Ca2+]i induced by different halothane
concentrations in human skeletal muscle cells. Single-cell intracellular
calcium measurements were performed with the ¯uorescent calcium
indicator fura-2/AM, using a Zeiss imaging system attached to an
Axiovert ¯uorescent microscope, as described in the Methods section.
Results are mean (SEM); the number of cells measured ranged between
132 and 246 for each halothane concentration and diagnostic group. The
halothane-induced increase in [Ca2+]i was signi®cantly different between
the three diagnostic groups (P<0.001) and between the different
halothane concentrations (P<0.0001; repeated measurements ANOVA).
Fisher's PLSD post-hoc test revealed signi®cant differences (P<0.001)
between all halothane concentrations, with the exception of 3.9 vs
4.6 mM.
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Switzerland. All other chemicals were reagent grade or of
highest available grade.
Human skeletal muscle cell cultures
Primary human muscle cell cultures were established from
surplus fragments taken from biopsies of patients undergo-
ing diagnostic IVCT as described previously.17 Cells were
grown in DME, 10% horse serum, insulin 5 ng ml±1, 2 mM
glutamine, antibiotics and 7 mM HEPES, pH 7.4 (pro-
liferative medium) under standard cell culture conditions.
For cryopreservation, about 106 cells were resuspended in
DME containing 40% FCS and 10% DMSO and were stored
in liquid nitrogen.
[Ca2+]i measurements
For measurements of [Ca2+]i, cells were trypsinized and
transferred from tissue culture ¯asks to glass coverslips and
allowed to grow in proliferative medium until groups of
cells were visible. We have previously demonstrated that
under these culture conditions the cells acquire skeletal-
muscle-speci®c proteins such as sarcomeric a-actinin and
type-1 RYR,17 although they do not fully differentiate into
multinuclear myotubes. Such primary cultures exhibit a
degree of variability in the maturity of individual cells.
Cells to be tested were loaded with the ¯uorescent
calcium indicator fura-2/AM. Single-cell calcium measure-
ments using ¯uorescence microscopy were performed on 10
cells before and after the addition of halothane. A new
coverslip containing fura-2/AM-loaded cells was used for
each halothane concentration. For each experiment a total of
72 digital images were recorded at excitations of 340 and
380 nm and the ratio calculated, as per our previous study.17
The values obtained during the ®rst 10 cells (i.e. before the
application of halothane) were used to calculate the resting
[Ca2+]i. Values were then taken during halothane perfusion
as well as after addition of EGTA/ionomycin and calcium
ions to obtain Rmin (the value obtained in the presence of
EGTA) and Rmax (the value obtained in the presence of high
Table 2 Halothane-induced changes (D) in [Ca2+]i, 340/380 nm ratio and integral calcium in primary cultures derived from MHN individuals: de®nition of
cut-off values
Percentile
Halothane concentration (mM) n 50th 75th 90th 95th 97th
D [Ca2+]i
3.9 198 31 50.6 85.1 110.3 117.2
4.6 198 47 74 101 127 137.9
5.7 205 72.7 105.5 167 203.5 230.6
7.2 178 106 158.6 239.2 310.4 507.2
8.6 173 139.5 265.6 391.4 513.8 570.5
D 340/380 nm ratio
3.9 198 0.07 0.09 0.13 0.15 0.176
4.6 198 0.09 0.13 0.17 0.201 0.233
5.7 205 0.13 0.187 0.27 0.347 0.409
7.2 178 0.2 0.28 0.35 0.376 0.43
8.6 173 0.25 0.422 0.57 0.677 0.733
Integral calcium
3.9 220 2.5 4.8 7.5 9.1 9.9
4.6 209 3.8 7.6 10.4 11.7 12.8
5.7 206 4.3 9.6 12 15.3 18.3
7.2 216 8.7 13.5 22 28.7 31.1
8.6 206 13.1 23.3 34.7 40.9 45.6
Table 3 Diagnosis of MH susceptibility by single-cell calcium measurements (changes in (D)[Ca2+]i, 340/380 nm ratio and integral calcium) compared with
in vitro contracture test (IVCT)-based diagnosis. MHN=MH negative; MHS=MH susceptible; MHE=MH equivocal
Diagnosis by IVCT
MHN MHE MHS
(n=18) (n=14) (n=22)
D [Ca2+]i >95th percentile 1 (6%) 4 (29%) 15 (68%)
D [Ca2+] i 97th percentile 0 2 (14%) 11 (50%)
D ratio >95th percentile 1 (6%) 5 (36%) 15 (68%)
D ratio >97th percentile 1 (6%) 4 (29%) 13 (59%)
Integral calcium >95th percentile 2 (11%) 7 (50%) 12 (55%)
Integral calcium >97th percentile 1 (6%) 5 (36%) 11 (50%)
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calcium after the addition of ionomycin). Each run lasted
approximately 6 min, including the time taken to run the
calibration at the end of the experiment. Halothane in
DMSO was administered at the indicated concentrations
from a gas-tight vial by means of a roller pump. Its actual
concentration was veri®ed by gas chromatography in
several test runs using ®xed ¯ow rates, temperature and
tubing. Calibration was performed using the EGTA/
ionomycin/manganese chloride method.18 The changes in
¯uorescence were converted into [Ca2+]i using the formula
[Ca2+]i=[kD3(R±Rmin)/(Rmax±R)] 3Sf2/Sb2, where kD (dis-
sociation constant) of fura-2/AM was assumed to be 225 nM
and Sf2 and Sb2 are the ¯uorescent values for Ca2+ free (f)
and bound (b) of the indicator. These values are a constant.
The ratios were analysed and converted into [Ca2+]i
values (nM) using a programmable database application
(Omnis 7/3 from Blyth Holding Inc., Suffolk, UK). The
increase in [Ca2+]i was determined by the difference
between resting [Ca2+]i and peak [Ca
2+]i after the addition
of halothane. The whole transient elicited by a given
halothane concentration was used to calculate the integral
calcium, which re¯ects the total amount of calcium
released.
Mutation screening
Screening for the presence of nine of the most frequent MH-
linked mutations (Arg163Cys, Gly341Arg, Arg614Cys,
Arg614Leu, Arg2163Cys, Val2168Met, Gly2434Arg,
Arg2458Cys, Arg2458His) was performed by genomic
DNA PCR ampli®cation followed by restriction enzyme
digestion and polyacrylamide gel electrophoresis. Total
genomic DNA was isolated from either peripheral blood or
muscle fragments not used for IVCT. PCR conditions and
primer sequences were as described previously.19
Statistical analysis
The [Ca2+]i measurements from the three diagnostic groups
were compared using repeated measurements ANOVA.
Within each halothane concentration, the results from the
three diagnostic groups were compared using Fishers's
protected least signi®cant difference (PLSD) post-hoc test.
To determine normal [Ca2+]i values, all measurements of
the MHN cells were pooled and median values, as well as
75th, 90th, 95th, 97th and 99th percentiles, were calculated
for each halothane concentration. These percentile values
were used to de®ne different cut-off values. Median values
were calculated for each individual at the ®ve halothane
concentrations and compared with the cut-off values de®ned
by the MHN population. If the cut-off value was exceeded at
any concentration of halothane, the patient was classi®ed as
MHS.
StatView (SAS Institute Inc., Cary, NC, USA) was used
for statistical analysis.
Results
MH phenotyping by [Ca2+]i measurements
We investigated intracellular calcium homeostasis in pri-
mary skeletal muscle cells obtained from 22 individuals
diagnosed as MHS, 14 individuals diagnosed as MHE and
18 individuals diagnosed as MHN by IVCT, according to
the European MH Group protocol. Single-cell [Ca2+]i
measurements were performed at the ®ve halothane con-
centrations in 10 fura-2/AM-loaded cells; the ¯uorescent
changes induced by halothane were converted into [Ca2+]i
values by performing signal calibration at the end of each
experiment. Some cells contracted when high intracellular
calcium concentrations were reached, so the ¯uorescence
signal could not be calibrated. These cells were therefore
excluded from Figure 1, in which we show the peak [Ca2+]i
induced by halothane. The results depicted in Figure 1 show
that halothane-induced increases in [Ca2+]i in primary
skeletal muscle cells differed signi®cantly between MHS,
MHE and MHN individuals. The increases in [Ca2+]i were
dose dependent (P<0.0001; repeated measurements
ANOVA; Figure 1). In addition, the increases in [Ca2+]i in
muscle cells from MHS and MHE individuals were shifted
to lower halothane concentrations when compared with
cells from MHN individuals (P<0.0001; repeated measure-
ments ANOVA, Figure 1). Fisher's PLSD post-hoc test
revealed signi®cant differences (P<0.001) between all
Fig 2 Receiver operating characteristic (ROC) curve comparing the
diagnostic results of [Ca2+]i measurements at different cut-off values
(50±99th percentile) with IVCT diagnosis. The curve shows sensitivity
and speci®city of the [Ca2+]i measurements for the diagnosis of MH
susceptibility.
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halothane concentrations, with the exception of 3.9 vs
4.6 mM.
Cut-off values for the determination of MH susceptibility
by [Ca2+]i measurements were calculated on the basis of
results from the individuals diagnosed as MHN by the IVCT
and are presented in Table 2. Using the 95th percentile as a
cut-off value, MH susceptibility was diagnosed by meas-
urements of [Ca2+]i in 15 of 22 MHS patients (68%), 4 of 14
MHE patients (29%) and 1 of 18 MHN patients (6%)
(Table 3). We calculated sensitivity and speci®city by
comparing results obtained by the [Ca2+]i measurements
with results obtained by the IVCT. Using the 95th percentile
as a cut-off value, the speci®city was 0.94 (95% con®dence
intervals [CI] 0.73 to 1.0, Table 3, Fig. 2) and the sensitivity
was 0.68 (95% CI 0.45 to 0.86). Taking into account that the
speci®city of the IVCT using the European MH Group
protocol is 0.93,20 the actual number of MHS could be 20
instead of 22. This would increase the sensitivity of [Ca2+]i
measurements to 0.75 (95% CI 0.51 to 0.91).
Effect of RYR1 gene mutations on halothane-induced
increases in [Ca2+]i
We next investigated whether the presence of different
RYR1 gene mutations has an impact on halothane-induced
[Ca2+]i transients and whether cells from different patients
carrying the same mutation respond in a similar way.
Figure 3 shows a box plot of the halothane-induced [Ca2+]i
transients (peak [Ca2+]i and total amount of [Ca
2+]i
released) from individuals carrying four different MH-
linked mutations. The increase in [Ca2+]i is particularly
evident at halothane concentrations >5.7 mM and was
irrespective of the mutation.
The halothane `trigger concentration' appears to vary
between individuals with different mutations.19 21 In order
to study if this is speci®c for a given mutation or a more
general phenomenon, we analysed the halothane-induced
peak [Ca2+]i in cells obtained from unrelated individuals
carrying the same Val2168Met mutation. Halothane trigger
concentrations and peak [Ca2+]i were different in these
unrelated individuals (Fig. 4), suggesting that the genetic
background in¯uences the halothane-induced increase in
[Ca2+]i.
Discussion
In the present report we show that halothane-induced
increases in [Ca2+]i in human skeletal muscle cells can be
used to phenotype MH susceptibility. However, our results
show that different mutations in the RYR1 gene have no
speci®c effect on halothane-induced increases in [Ca2+]i.
Measurements of halothane-induced increases in [Ca2+]i in
human skeletal muscle cells con®rmed the IVCT diagnosis
of MH susceptibility in 15 of 22 MHS individuals (68%)
when the 95th percentile of the values obtained from the
MHN population was used as a cut-off value. Taking into
account that the speci®city of the IVCT following the
protocol of the European MH Group is 0.93, this could
reduce the number of MHS individuals to 20, leading to an
increase in the number of coinciding MHS diagnoses (15 of
20, 75%). Only one MHN individual exceeded the 95th
percentile cut-off value. This discordance could be due to
either a wrong IVCT diagnosis or oversensitivity of
diagnosis based on measurements of halothane-induced
increases in [Ca2+]i.
In seven of 22 individuals the IVCT diagnosis of MHS
could not be con®rmed by halothane-induced increases in
[Ca2+]i. This could be due to either a reduced speci®city of
the IVCT (not every MHS diagnosis can be con®rmed by
molecular genetic analysis), or to an overestimation of the
halothane-induced increases in [Ca2+]i of the true `normal'
populationÐin the present study `normal' [Ca2+]i values
were obtained from individuals from MHS families, not
from non-MH-linked individuals.
In this study we con®rm and extend our previous results.
In fact, our earlier work was based on observations carried
out on two MHS subjects and three MHN subjects while in
this study we also included 14 MHE individuals, and the
number of patients involved was 10 times larger. In the
study by Censier and colleagues,17 we observed that the
maximum difference between MHS and MHN, as far as
halothane-induced increases in [Ca2+]i are concerned,
occurred at halothane concentrations of 5.7±9.5 mM. In
addition, we con®rm that the mean increase in [Ca2+]i of
cells from MHN individuals occurring at 8.6 mM halothane
is similar to that of cells from MHS individuals at 5.7 mM
halothane (203 nM vs 167 nM, respectively; P=0.269,
student's t-test for unpaired samples).
The response of cells presented in our previous
report17 seem to be different from those found in this
study. In the present study we examined a larger sample
than previously and we believe that the values obtained
are more likely to represent the MHN population. We
would like to point out that it is very important to
perform [Ca2+]i measurements at several halothane
concentrations and we suggest concentrations ranging
around 5.7 mM since this is the concentration where
maximal differences can be observed.
Fig 3 Halothane-induced [Ca2+]i response of cultured human skeletal muscle cells for four individuals. Single-cell [Ca
2+]i measurements were
performed as described in Figure 1. The box plot shows median peak D [Ca2+]i and median total calcium release induced at each halothane
concentration, together with 10th, 25th, 75th and 90th percentiles. Panels A, C, E and G show the peak [Ca2+]i; panels B, D, F and H show total amount
of calcium released (arbitrary units, a.u.) by halothane in individuals carrying the indicated RYR1 mutation. Mutation screening was performed as
described in the Methods section.
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In this study we used small fragments of tissue (2±4 mm3)
left over from muscle biopsies. We have already assessed
the feasibility of obtaining primary cultures from needle
biopsies (unpublished observations). This approach offers
obvious physical advantages for the patients, as well as
being cheaper. Obviously there are some limitations in the
use of this novel approach: (i) the need for cell culture and
¯uorescent calcium imaging facilities, (ii) the fact that cells
cultured from the biopsies give rise to heterogeneous cell
populations that do not respond to halothane in a uniform
way, (iii) not all individuals diagnosed as MHS by IVCT
had an halothane-induced increase in [Ca2+]i beyond that of
the MHN population.
As to the future of MH diagnostics, one can envisage that
individuals from families with de®ned mutations could ®rst
undergo genetic testing.22 If no mutation is found, they
could undergo a skeletal muscle needle biopsy followed by
measurements of halothane-induced increases in [Ca2+]i. If
measurements of [Ca2+]i do not reveal MH susceptibility,
then an IVCT could be performed. With this less invasive
and stepwise approach, the high sensitivity of the IVCT and
thus the high safety level of MH diagnostics is maintained.
In fact if these criteria were used, only three of the 22 MHS
individuals and seven of the 14 MHE individuals would still
require the invasive IVCT. For the time being, however, all
the MHN individuals would still require IVCT testing.
The common ®nal pathway for MH is the loss of the ®ne
regulation of calcium homeostasis in muscle cells. The
present investigation is not only potentially important from
a clinical point of view, but also from a biological one. In
fact, it indicates that although a variety of factors such as
metabolic processes, muscle training, protein composition
Fig 4 Halothane-induced [Ca2+]i response of cultured human skeletal muscle cells from single members of four families carrying the same
Val2168Met mutation (families D, C and F ± as given in Table 1; the individual shown in panel a was the only member of this family investigated).
Median peak D [Ca2+]i induced by each halothane concentration, together with 10th, 25th, 50th, 75th and 90th percentile are shown in the box plot.
Conditions are described in the legend to Figure 1.
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and enzyme activation may in¯uence the IVCT (at least as
far as contracture force is concerned), there is an intrinsic
`defect' in the machinery involved in [Ca2+]i homeostasis in
MHS individuals. Each individual may compensate for the
molecular defect in a variety of ways, which may be
in¯uenced by the speci®c mutation present as well as other
genetic and `environmental' factors. This hypothesis is
supported by the fact that the halothane-induced changes in
[Ca2+]i in cells from MHS individuals bearing the same
point mutation but with a different genetic background do
not coincide, and because MHS individuals with RYR1
mutations do not undergo MHS reactions at every contact
with trigger agents.4 5 Our results also show that the
penetrance of a given mutation varies between individuals.
This observation would be expected in view of the fact that
the RYR must assemble as a tetramer in order to function as
a calcium channel. The results of this study, as well as data
from IVCT, tend to favour the hypothesis that mutated
channels are probably randomly distributed, giving rise to
`heterogeneous' responses, but the presence of a single
mutated channel is suf®cient to confer the MHS phenotype.
This hypothesis is supported by our previous work,17 in
which the normal phenotype was not reconstituted by
transfecting MHS cells with wild-type channels.
In conclusion, measurements of [Ca2+]i may be useful in
increasing the accuracy of MH phenotyping and may
therefore be used as a complementary method for the
diagnosis of MH susceptibility.
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